Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA. Govers TM, et al. Among authors: van criekinge w. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109. doi: 10.1038/s41391-018-0076-3. Epub 2018 Aug 20. Prostate Cancer Prostatic Dis. 2019. PMID: 30127462
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, Hulsbergen-van de Kaa CA, Klaver OS, Sedelaar JPM, Van Criekinge W, de Jong H, Mulders PFA, Crawford ED, Veltman J, Schalken JA, Barentsz JO, van Oort IM. Hendriks RJ, et al. Among authors: van oort im, van criekinge w, van der leest mmg. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1110-1119. doi: 10.1038/s41391-021-00367-8. Epub 2021 May 3. Prostate Cancer Prostatic Dis. 2021. PMID: 33941866 Free PMC article.
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA. Van Neste L, et al. Among authors: van oort im, van criekinge w. Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20. Eur Urol. 2016. PMID: 27108162
Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Hendriks RJ, Dijkstra S, Smit FP, Vandersmissen J, Van de Voorde H, Mulders PFA, van Oort IM, Van Criekinge W, Schalken JA. Hendriks RJ, et al. Among authors: van oort im, van criekinge w, van de voorde h. Prostate. 2018 Apr;78(5):336-342. doi: 10.1002/pros.23477. Epub 2018 Jan 12. Prostate. 2018. PMID: 29330943 Free PMC article.
Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population.
Rubio-Briones J, Borque-Fernando A, Esteban LM, Mascarós JM, Ramírez-Backhaus M, Casanova J, Collado A, Mir C, Gómez-Ferrer A, Wong A, Aragón F, Calatrava A, López-Guerrero JA, Groskopf J, Schalken J, Van Criekinge W, Domínguez-Escrig J. Rubio-Briones J, et al. Among authors: van criekinge w. Prostate. 2020 May;80(6):500-507. doi: 10.1002/pros.23964. Epub 2020 Feb 20. Prostate. 2020. PMID: 32077525
Epigenetic risk score improves prostate cancer risk assessment.
Van Neste L, Groskopf J, Grizzle WE, Adams GW, DeGuenther MS, Kolettis PN, Bryant JE, Kearney GP, Kearney MC, Van Criekinge W, Gaston SM. Van Neste L, et al. Among authors: van criekinge w. Prostate. 2017 Sep;77(12):1259-1264. doi: 10.1002/pros.23385. Epub 2017 Aug 1. Prostate. 2017. PMID: 28762545
179 results